Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Dodwell

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
ESMO Real World Data and Digital Oncology|May 4, 2026
Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023)V Perletta, S Kulkarni, Z Wang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 9, 2024
Estimated Doses to the Heart, Lungs and Oesophagus and Risks From Typical UK Radiotherapy for Early Breast Cancer During 2015-2023F Holt, A Ivanova, Z Wang, et al.
Journal of Bone Oncology|February 25, 2016
Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trialJ E Lester, D Dodwell, J E Brown, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 8, 2019
International Variation in Criteria for Internal Mammary Chain RadiotherapyF K Duane, P McGale, S Teoh, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastasesR E Coleman, L Y Dirix, D Dodwell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 1, 2020
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised TrialJ F Seligmann, A Wright-Hughes, A Pottinger, et al.
NPJ Breast Cancer|February 13, 2026
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumourS Blacker, K Horgan, D A Cromwell, et al.
British Journal of Cancer|November 26, 2014
Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional studyE A Rakha, P H Tan, Z Varga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclinesM Martin, M Spielmann, M Namer, et al.
British Journal of Cancer|March 18, 2010
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerR E Coleman, M C Winter, D Cameron, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
ESMO Real World Data and Digital Oncology|May 4, 2026
Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023)V Perletta, S Kulkarni, Z Wang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 9, 2024
Estimated Doses to the Heart, Lungs and Oesophagus and Risks From Typical UK Radiotherapy for Early Breast Cancer During 2015-2023F Holt, A Ivanova, Z Wang, et al.
Journal of Bone Oncology|February 25, 2016
Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trialJ E Lester, D Dodwell, J E Brown, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 8, 2019
International Variation in Criteria for Internal Mammary Chain RadiotherapyF K Duane, P McGale, S Teoh, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastasesR E Coleman, L Y Dirix, D Dodwell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 1, 2020
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised TrialJ F Seligmann, A Wright-Hughes, A Pottinger, et al.
NPJ Breast Cancer|February 13, 2026
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumourS Blacker, K Horgan, D A Cromwell, et al.
British Journal of Cancer|November 26, 2014
Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional studyE A Rakha, P H Tan, Z Varga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclinesM Martin, M Spielmann, M Namer, et al.
British Journal of Cancer|March 18, 2010
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerR E Coleman, M C Winter, D Cameron, et al.
Pageof 9